CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3 enrolled
Drug / intervention
Ir-192 high dose rate (HDR)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01757717
NCT01757717N/ACompleted
CompareCT.gov

A Pilot Study of Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

Memorial Sloan Kettering Cancer Center·interventional·Posted Dec 31, 2012·Updated Mar 20, 2018

In Brief

A clinical study evaluating Ir-192 high dose rate (HDR) for Metastatic or Recurrent Lesions in the Spine and Metastatic or Recurrent Lesions in the Pelvis. Completed, enrolled 3 participants across 1 site.

Detailed Summary

The purpose of this study is to see if using a form of imaging during surgery helps the doctors to guide the placement of radiation catheters more accurately. This method, called "image-guided surgical navigation" may allow the doctors to deliver radiation to the tumor that the patient needs and decrease the amount of radiation delivered to the nearby areas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic or Recurrent Lesions in the Spine, Metastatic or Recurrent Lesions in the Pelvis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 31, 2012
Enrollment StartJan 1, 2013
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.5 years ago

Interventions

Ir-192 high dose rate (HDR)radiation

Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.